This early phase I studies the side effects of dendritic cell survivin vaccine and how well it works in treating patients with multiple myeloma who are undergoing stem cell transplant. Vaccines made from a gene-modified virus may help the body build an effective immune response to kill cancer cells.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT02851056.
PRIMARY OBJECTIVES:
I. Determine the safety of DC:AdmS (dendritic cell survivin vaccine) when administered to patients with myeloma before and around day +21 after autologous hematopoietic stem cell transplant.
II. Evaluate the ability of DC:AdmS to induce T cell immune responses against survivin when administered to patients with myeloma before and at day +21 after autologous hematopoietic stem cell transplant.
OUTLINE:
Patients receive first dose dendritic cell survivin vaccine intradermally (ID) 7-30 days before apheresis collection and second dose 20-34 days following stem cell transplantation in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 60, 90, and 180 days.
Lead OrganizationMoffitt Cancer Center
Principal InvestigatorFrederick Lundry Locke
